News & Research - HBM Partners AG

NEWS & RESEARCH

NEWS & RESEARCH

NEWS & RESEARCH

1

Portfolio News

HBM in the News

HBM M&A Report

Shape Memory Medical Completes Enrollment in the AAA-SHAPE Early Feasibility Study (958 KB)
29.08.2022
Download
Upstream Bio Announces Dosing of First Patient in a Phase 1b Clinical Trial of UPB-101 in Asthma (149 KB)
9.8.2022
Download
Vascular Dynamics Completes $20 Million Equity Financing to Support Further Clinical Evaluations of MobiusHD Device (117 KB)
12.07.2022
Download
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC (64 KB)
29.06.2022
Download
Aculys Pharma initiates collaboration with Ubie with the aim of building a "sleep ecosystem" (544 KB)
29.06.2022
Download
Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic (195 KB)
28.06.2022
Download
Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial and Urothelial Cancer Patients Based on Predicted Sensitivity to ACR-368 (167 KB)
22.06.2022
Download
Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC (69 KB)
16.06.2022
Download
Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic (165 KB)
14.06.2022
Download
Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension (189 KB)
08.06.2022
Download

Trump lässt Pharmaanleger erschauern (165 KB)
12.1.2017
Download Read more
Andreas Wicki, CEO HBM Healthcare Investments, im Interview (190 KB)
12.9.2016
Download Read more
Im Schweizer Biotech-Segment ist viel Feingefühl gefragt (164 KB)
3.8.2016
Download Read more
Suche nach dem Superwirkstoff gegen Krebs (147 KB)
7.5.2016
Download Read more

HBM Biopharma M&A Report 2022

HBM Biopharma M&A Database 2005-2022 (Excel)

© HBM Partners AG | Bundesplatz 1 | 6300 Zug, Switzerland | Phone +41 43 888 7171